Santen Pharmaceutical Co., Ltd. (SNPHF)
USD 10.53
(0.0%)
USD 10.53
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | 72.37 JPY | 287.58% |
| 2023 | -38.58 JPY | -156.68% |
| 2022 | 68.07 JPY | 298.07% |
| 2021 | 17.10 JPY | -71.1% |
| 2020 | 59.16 JPY | -24.8% |
| 2019 | 78.67 JPY | -9.32% |
| 2018 | 86.76 JPY | 63.82% |
| 2017 | 52.96 JPY | -58.94% |
| 2016 | 128.99 JPY | 121.71% |
| 2015 | 58.18 JPY | 21.77% |
| 2014 | 47.78 JPY | 22.01% |
| 2013 | 39.16 JPY | -0.58% |
| 2012 | 39.39 JPY | -21.13% |
| 2011 | 49.94 JPY | 13.45% |
| 2010 | 44.02 JPY | 84.8% |
| 2009 | 23.82 JPY | -18.51% |
| 2008 | 29.23 JPY | -3.59% |
| 2007 | 30.32 JPY | 0.9% |
| 2006 | 30.05 JPY | 19.39% |
| 2005 | 25.17 JPY | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 FY | - JPY | 288.15% |
| 2024 Q1 | 27.93 JPY | 843.58% |
| 2024 Q4 | 0.08 JPY | -99.6% |
| 2024 Q3 | 20.73 JPY | -15.73% |
| 2024 Q2 | 24.60 JPY | -11.92% |
| 2023 Q1 | 16.79 JPY | -15.16% |
| 2023 Q3 | 15.49 JPY | 120.49% |
| 2023 FY | - JPY | -156.68% |
| 2023 Q4 | 2.96 JPY | -80.89% |
| 2023 Q2 | -75.59 JPY | -550.21% |
| 2022 Q3 | 12.60 JPY | -27.71% |
| 2022 Q2 | 17.43 JPY | -5.58% |
| 2022 Q1 | 18.46 JPY | 152.24% |
| 2022 Q4 | 19.79 JPY | 57.06% |
| 2022 FY | - JPY | 298.07% |
| 2021 Q1 | 15.49 JPY | 85.07% |
| 2021 FY | - JPY | -71.1% |
| 2021 Q3 | 17.98 JPY | -5.81% |
| 2021 Q4 | -35.34 JPY | -296.55% |
| 2021 Q2 | 19.09 JPY | 23.24% |
| 2020 FY | - JPY | -24.8% |
| 2020 Q4 | 8.37 JPY | -53.29% |
| 2020 Q3 | 17.92 JPY | 5.97% |
| 2020 Q1 | 16.03 JPY | -23.92% |
| 2020 Q2 | 16.91 JPY | 5.49% |
| 2019 Q4 | 21.07 JPY | -4.66% |
| 2019 FY | - JPY | -9.32% |
| 2019 Q1 | 16.85 JPY | -13.46% |
| 2019 Q2 | 18.49 JPY | 9.73% |
| 2019 Q3 | 22.10 JPY | 19.52% |
| 2018 Q2 | 15.36 JPY | -30.81% |
| 2018 FY | - JPY | 63.82% |
| 2018 Q4 | 19.47 JPY | -34.47% |
| 2018 Q3 | 29.71 JPY | 93.42% |
| 2018 Q1 | 22.20 JPY | 178.89% |
| 2017 FY | - JPY | -58.94% |
| 2017 Q4 | 7.96 JPY | -55.05% |
| 2017 Q3 | 17.71 JPY | 41.45% |
| 2017 Q2 | 12.52 JPY | -29.19% |
| 2017 Q1 | 17.68 JPY | 109.98% |
| 2016 Q4 | 8.42 JPY | -44.05% |
| 2016 Q2 | 87.28 JPY | 378.51% |
| 2016 FY | - JPY | 121.71% |
| 2016 Q1 | 18.24 JPY | -3.85% |
| 2016 Q3 | 15.05 JPY | -82.76% |
| 2015 FY | - JPY | 21.77% |
| 2015 Q3 | 18.17 JPY | 31.76% |
| 2015 Q1 | 9.84 JPY | 134.29% |
| 2015 Q2 | 13.79 JPY | 40.14% |
| 2015 Q4 | 18.97 JPY | 4.4% |
| 2014 Q2 | 8.32 JPY | -38.28% |
| 2014 Q3 | 15.46 JPY | 85.82% |
| 2014 Q4 | 4.20 JPY | -72.83% |
| 2014 FY | - JPY | 22.01% |
| 2014 Q1 | 13.48 JPY | 133.22% |
| 2013 Q1 | 9.81 JPY | 78.69% |
| 2013 Q2 | 10.79 JPY | 9.99% |
| 2013 Q3 | 12.50 JPY | 15.85% |
| 2013 FY | - JPY | -0.58% |
| 2013 Q4 | 5.78 JPY | -53.76% |
| 2012 FY | - JPY | -21.13% |
| 2012 Q4 | 5.49 JPY | -50.76% |
| 2012 Q1 | 12.69 JPY | -17.0% |
| 2012 Q3 | 11.15 JPY | 10.95% |
| 2012 Q2 | 10.05 JPY | -20.8% |
| 2011 Q1 | 10.76 JPY | 84.25% |
| 2011 Q4 | 15.29 JPY | 20.39% |
| 2011 FY | - JPY | 13.45% |
| 2011 Q2 | 11.03 JPY | 2.51% |
| 2011 Q3 | 12.70 JPY | 15.14% |
| 2010 Q1 | 15.40 JPY | 171.13% |
| 2010 FY | - JPY | 84.8% |
| 2010 Q4 | 5.84 JPY | -45.62% |
| 2010 Q2 | 12.05 JPY | -21.75% |
| 2010 Q3 | 10.74 JPY | -10.87% |
| 2009 FY | - JPY | -18.51% |
| 2009 Q2 | 8.27 JPY | 0.0% |
| 2009 Q3 | 9.18 JPY | 11.0% |
| 2009 Q4 | 5.68 JPY | -38.13% |
| 2008 FY | - JPY | -3.59% |
| 2007 FY | - JPY | 0.9% |
| 2006 FY | - JPY | 19.39% |
| 2005 FY | - JPY | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AstraZeneca PLC | 3.84 USD | -1784.635% |
| Bristol-Myers Squibb Company PFD CONV 2 | 3.88 USD | -1765.206% |
| CSPC Pharmaceutical Group Limited | 0.07 USD | -103285.714% |
| Clarus Therapeutics Holdings, Inc. | -8.04 USD | 1000.124% |
| Novartis AG | 7.63 USD | -848.493% |
| PT Kalbe Farma Tbk. | 0.00 USD | -1855541.026% |